Portfolio Manager Factsheet

October 2017

Celgene shares underperformed due to the failure of a late-stage clinical program, and due to reduced long-term financial guidance. Aerie Pharmaceuticals, Puma Biotechnology, and Illumina were the top positive contributors to performance during the month.

Read more »

Register for email alerts

The Biotech Growth Trust PLC conducts its affairs so that its shares can be recommended by independent financial advisers (IFAs) to retail private investors. The shares are excluded from the Financial Conduct Authority's (FCA's) restrictions which apply to non-mainstream investment products because they are shares in a UK-listed investment trust.